Etanercept
- Generic Name
- Etanercept
- Brand Names
- Enbrel, Eticovo, Benepali, Erelzi, Nepexto
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 185243-69-0
- Unique Ingredient Identifier
- OP401G7OJC
- Background
Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technolo...
- Indication
Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis and Juvenile Psoriatic Arthritis in those aged 2 years and older. Etanercept is al...
- Associated Conditions
- Active Juvenile Psoriatic Arthritis, Ankylosing Spondylitis (AS), Graft-versus-host Disease (GVHD), Polyarticular Juvenile Idiopathic Arthritis, Psoriasis Vulgaris (Plaque Psoriasis), Psoriatic Arthritis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Plaque psoriasis, Stevens-Johnson Syndrome, Chronic, severe Psoriatic Arthritis, Moderate Plaque psoriasis, Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis
- Associated Therapies
- -
Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation
- First Posted Date
- 2015-01-01
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- University Hospitals Cleveland Medical Center
- Target Recruit Count
- 26
- Registration Number
- NCT02330380
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
An Observational Monocentric Study Investigating the Association Between Trough Serum Levels of Etanercept, Antibodies Towards Etanercept and Its Effectiveness in Psoriasis Patients
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 56
- Registration Number
- NCT02322580
A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs
- Conditions
- Interventions
- First Posted Date
- 2014-12-04
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 509
- Registration Number
- NCT02308163
- Locations
- 🇯🇵
JP00099, Chiyoda, Tokyo, Japan
🇯🇵JP00018, Fukuoka, Japan
🇯🇵JP00078, Kawachinagano, Osaka, Japan
Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With Plaque Psoriasis
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2016-12-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 132
- Registration Number
- NCT02274792
- Locations
- 🇨🇦
Research Site, Waterloo, Ontario, Canada
Safety and Efficacy of Etanercept in Patients With Psoriasis
- First Posted Date
- 2014-10-07
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Chengdu PLA General Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT02258282
- Locations
- 🇨🇳
General Hospital of Chengdu Military Area Command PLA, Chengdu, Sichuan, China
Study With Etanercept Focusing on Remission and Predictability of Remission in Real Life Clinical Practice
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2018-12-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 157
- Registration Number
- NCT02202837
- Locations
- 🇧🇪
ASZ Aalst, Aalst, Belgium
🇧🇪AZ Groeninge Campus Sint Maarten, Kortrijk, Belgium
🇧🇪CHU Ambroise Pare, Mons, Belgium
Defining Remission With Etanercept in AS in Real Life Clinical Practice
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2018-11-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 84
- Registration Number
- NCT02202850
- Locations
- 🇧🇪
Grand Hopital de Charleroi, Gilly, Belgium
🇧🇪Algemeen Stedelijk Ziekenhuis, Aalst, Belgium
🇧🇪Biomedical Research Institute/ Department of Rheumatology, Genk, Belgium
Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2014-05-22
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- University of Athens
- Target Recruit Count
- 200
- Registration Number
- NCT02144857
- Locations
- 🇬🇷
Attikon Hospital, Athens, Greece
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
- First Posted Date
- 2014-05-09
- Last Posted Date
- 2019-06-28
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 521
- Registration Number
- NCT02134210
- Locations
- 🇺🇸
Radiant Research - Atlanta, Atlanta, Georgia, United States
🇺🇸Healthcare Partners Medical Group, Torrance, California, United States
🇺🇸Atlantic Clinical Research Collaborative, West Palm Beach, Florida, United States
Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
- First Posted Date
- 2014-05-07
- Last Posted Date
- 2014-05-07
- Lead Sponsor
- Jagiellonian University
- Target Recruit Count
- 100
- Registration Number
- NCT02132234
- Locations
- 🇵🇱
Katedra Chorób Wewnętrznych i Medycyny Wsi, Uniwersytet Jagielloński, Krakow, Skarbowa 4, Poland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.